This study investigatedthe efficacy and safety offluticasone propionate nasal spray in treatment of adenoidal hypertrophic snoring in children.Fifty-six children with adenoidal hypertrophic snoring ...

In a phase 3 trial, toripalimab-based chemotherapy with radiotherapy without concurrent cisplatin achieved noninferior 3-year failure-free survival compared with standard therapy in patients with ...

For gene therapy to work well, therapeutic molecules need to be efficiently delivered to the correct locations in the body -- a job commonly given to adeno-associated viruses (AAV). To improve the AAV ...

As a first-line therapy, the risk of disease progression or death was reduced by 55% in the pempulimab-kcqx group vs the placebo group. The Food and Drug Administration (FDA) has approved ...

Penpulimab-kcqx is approved for first-line treatment of recurrent or metastatic non-keratinizing NPC in combination with cisplatin or carboplatin and gemcitabine. As a single agent, penpulimab-kcqx is ...

Adjuvant therapy with camrelizumab significantly improved 3-year event-free survival in patients with locoregionally advanced nasopharyngeal carcinoma compared with observation, according to findings ...

Adenoid hypertrophy (AH) is characterized by pathological hyperplasia of the nasopharyngeal tonsils, a component of Waldryer’s ring, which represents the first immune defense of the upper respiratory ...

Nasal valve collapse causes the airways in the nose to narrow. This can result in breathing difficulties and significantly affect a person’s quality of life. Surgery is often necessary, but ...

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274 Sixteen towns in Sihui and Zhongshan cities, China, were selected; eight were randomly ...

Camrelizumab increased the 3-year event-free survival rate vs standard of care from 77.3% to 86.9%, translating to a 44% reduced risk of death or relapse in patients with nasopharyngeal carcinoma. The ...